— ‘The Changing Faces of Beauty: A Global Report’ reveals women across the world are more open to enhancing how they look
— Desire to boost self-confidence now considered equally as important as aesthetics when it comes to considering beauty treatments /PRNewswire/ — Allergan plc (NYSE: AGN), a global medical aesthetics company and the makers of Juvéderm® facial fillers today announces the results of a new global beauty trends study. It reveals women are more aware and open to aesthetic enhancement and are taking control of how ageing affects their appearance as a way to feel more confident about themselves. According to ‘The Changing Face of Beauty: A Global Report’, female beauty is no longer driven solely by a desire to look younger – women want to control how they look as a way to change how they feel as an individual. read more
Elsevier to Develop First-ever Benchmark Report on US Cancer Research Landscape
Report Will Provide a Comprehensive View of the US Cancer Research for the National Cancer Moonshot Initiative
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced an initiative with the White House National Cancer Moonshot Task Force to develop a comprehensive study of cancer research in the United States.
The Elsevier report will provide a road map of the cancer research landscape to identify pockets of expertise and opportunity and will be made available for free. It is intended to equip the leaders of the National Cancer Moonshot Initiative and other public and private interests with the data and analytics necessary to make informed decisions about research investments that will accelerate cancer activities while mitigating some of the investment risk and achieve a decade’s worth of advances in five years.
Heptares and Leadxpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery
Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and leadXpro AG (“leadXpro”), a new spin off from the Paul Scherrer Institute (PSI), announce a collaboration to employ powerful new approaches for the determination of high-resolution X-ray structures of G protein-coupled receptors (GPCRs) to discover new drug lead compounds.
GPCRs form one of the most important classes of drug targets, and Heptares is the world leader in the use of structure-based methods for GPCR drug discovery. leadXpro has deep expertise in biophysical and structure-based methods including serial crystallography and cryo-electron microscopy (cryo-EM), and applies these new techniques to the discovery and optimisation of innovative lead compounds targeting membrane proteins, such as GPCRs, ion channels and transporters.
Baxter Recognized as One of the Most Community-Minded Companies in the United States by Points of LighDEERFIELD, Ill. –(BUSINESS WIRE)–Jun. 28, 2016– Baxter International Inc. was recognized for the third consecutive year as one of the most community-minded companies in the nation, as a part of the Civic 50. Civic 50 is an initiative of Points of Light – the world’s largest organization dedicated to volunteer service, mobilizes millions of people to take action and change the world. Points of Light sets the standard for corporate civic engagement and creates a roadmap for companies seeking to best use their time, talent, and resources to improve the quality of life in the communities where they do business.
This year’s Civic 50 applicants were evaluated based on several criteria, including the quantity and impact of financial and human resources applied to civic improvement; whether internal and external resources are activated to maximize community impact; how a company’s community engagement activities support its business interests; how broadly community engagement is supported and institutionalized within a company’s policies, systems and incentives; and how a company measures the social and business value of its community engagement programs.
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis
Epclusa is the First and Only All-Oral, Pan-genotypic Single Tablet Regimen for Chronic Hepatitis C Virus Infection and Gilead’s Third Sofosbuvir-Based Regimen –
FOSTER CITY, Calif.–(BUSINESS WIRE)–Jun. 28, 2016– Gilead Sciences, Inc.(NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C).
Medtronic Announces Beacon Heart Failure Management Service, Furthering Its Commitment to Delivering Value in Healthcare
New Service Integrates Medtronic Device Data with Remote Patient Monitoring Solutions
DUBLIN – June 28, 2016 – Medtronic plc (NYSE:MDT) today announced availability of its Beacon Heart Failure Management Service in the United States. This new service from Medtronic Care Management Services (MCMS) combines data from Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS, enabling providers to focus on heart failure patients with the greatest risk and evaluate early intervention before a heart failure event occurs. read more
Egalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 for Lead Abuse-Deterrent Candidate ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
WAYNE, Pa., June 28, 2016 /PRNewswire/ — Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for August 4, 2016, to review the new drug application (NDA) for ARYMO™ ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate. ARYMO ER was developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.read more